NCT05187546

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

An Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Compared to Non-demented Controls (NDC)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Life Molecular Imaging GmbH · Industry
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The overall goal of this protocol is to evaluate the imaging characteristics of \[18F\]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)

Detailed description

The imaging characteristics of \[18F\]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS) will be evaluated by a) determining the test-retest variability of the \[18F\]PI-2620 binding parameters in brain of patients with PSP-RS and non-demented controls (NDC).

Conditions

• Progressive Supranuclear Palsy

Interventions

Type	Name	Description
DRUG	[18F]-PI2620	\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).

Timeline

• Start date: 2022-03-10
• Primary completion: 2024-02-29
• Completion: 2024-03-05
• First posted: 2022-01-12
• Last updated: 2025-05-18

Locations

1 site across 1 country: Germany